Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 05 2023 - 7:00AM
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage
precision oncology medicine company developing MasterKey therapies
designed to overcome limitations of existing therapies by targeting
families of oncogenic driver mutations in patients with genetically
defined cancers, today announced that its President and Chief
Executive Officer, David M. Epstein, Ph.D., will present an update
on the Company’s progress at the 41st Annual J.P. Morgan Healthcare
Conference on Thursday, January 12, 2023, at 9:00 a.m. PT in San
Francisco, California.
A live webcast of the presentation can be accessed by visiting
the investors relations section of the Company’s website at:
www.blackdiamondtherapeutics.com. A replay of the webcast will also
be available and archived for 90 days following the event.
About Black DiamondBlack Diamond Therapeutics
is a clinical-stage precision oncology medicine company focused on
the development of MasterKey therapies that target families of
oncogenic mutations in clinically validated targets. Black Diamond
leverages a deep understanding of cancer genetics and onco-protein
structure and function, to discover and develop innovative
MasterKey therapies. The Company’s MasterKey therapies are designed
to overcome resistance, minimize on-target, wild-type mediated
toxicities, and be brain penetrant to address significant unmet
medical needs of patients with genetically defined cancers. The
Company is advancing a robust pipeline with lead clinical-stage
program BDTX-1535, targeting MasterKey mutations in both EGFR
mutant-positive non-small cell lung cancer (NSCLC) and in
glioblastoma multiforme (GBM), and BDTX-4933, a program targeting
RAF MasterKey mutations in solid tumors, as well as discovery-stage
research programs. The Company’s proprietary
Mutation-Allostery-Pharmacology, or MAP drug discovery engine, is
designed to allow Black Diamond to analyze population-level genetic
sequencing tumor data and validate MasterKey mutations.
Contact:Julie Seidel, Stern Investor
Relations(212) 362-1200investors@bdtx.commedia@bdtx.com
Black Diamond Therapeutics (NASDAQ:BDTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Black Diamond Therapeutics (NASDAQ:BDTX)
Historical Stock Chart
From Jul 2023 to Jul 2024